|
Secondary Neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Platelet-derived growth factor receptor-α (PDGFRα) is expressed in primary prostate adenocarcinoma and in associated skeletal metastases.
|
30573277 |
2019 |
|
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
When either PDGFRα or PDGF-AA was used to predict the presence of metastases, the sensitivity achieved was 86% and 88%, respectively, whereas specificities were lower at 71% and 61%, respectively.
|
29408504 |
2018 |
|
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
The presented work has the potential to allow physicians to identify papillary thyroid cancer patients at risk of metastases by using the novel immuno-PET imaging assay based on PDGFRα-targeting antibody [<sup>64</sup>Cu]Cu-NOTA-D13C6.
|
29367096 |
2018 |
|
Secondary Neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Therefore, PDGFRα expression distinguishes two functionally unique CAF populations in breast tumors and metastases and may have important implications for patient stratification and precision therapeutics.
|
30470719 |
2018 |
|
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Population Pharmacokinetic Modeling of Olaratumab, an Anti-PDGFRα Human Monoclonal Antibody, in Patients with Advanced and/or Metastatic Cancer.
|
28620891 |
2018 |
|
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
PDGFRa amplification in multiple skin lesions of undifferentiated pleomorphic sarcoma: A clue for intimal sarcoma metastases.
|
28105789 |
2017 |
|
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
However, it is unclear how PDGFRα potentiates metastases and if it works through the canonical MAPK pathway traditionally linked to PTC oncogenesis.
|
27845909 |
2016 |
|
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Patients exhibiting PDGFRα at time of diagnosis are three times more likely to exhibit nodal metastases and are 18 times more likely to recur within 5years than those patients lacking PDGFRα expression.
|
27682510 |
2016 |
|
Secondary Neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We analyzed 53 PDGFRA-mutated GISTs (including 2 with corresponding metastases) for chromosomal imbalances by conventional comparative genomic hybridization and compared them with a historical collective of 122 KIT-mutated GISTs.
|
24157063 |
2014 |
|
Secondary Neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Mutational analysis (quantitative polymerase chain reaction) for KIT exons 9, 11, 13 and 17 and PDGFRa exon 18 was performed on paraffin-embedded tissue (40 primary tumours and three metastases).
|
23171083 |
2014 |
|
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Induction of PDGFRα and invadopodia is essential for Twist1 to promote tumor metastasis.
|
21397860 |
2011 |
|
Secondary Neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The 5 cases of GIST were positive for PDGFRA protein, suggesting that PDGFRA overexpression is not associated with PDGFRA gene mutations.Four of the 31 cases showed metastases.
|
20126584 |
2009 |
|
Secondary Neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Most sporadic gastrointestinal stromal tumors (GISTs) occur solitary, whereas a multicentric appearance is suspicious for a familial or syndromal setting such as with germline mutations of proto-oncogene tyrosine protein kinase Kit (KIT) or platelet derived growth factor receptor alpha (PDGFRA), or even for metastases.
|
17527083 |
2007 |